Telavancin

Results: 19



#Item
1HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ® VIBATIV (telavancin) safely and effectively. See full prescribing information for VIBATIV.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ® VIBATIV (telavancin) safely and effectively. See full prescribing information for VIBATIV.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-12-04 13:27:31
2Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/ November 7, [removed]Theravance, Inc., and Astellas Pharma Inc. announced t

Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/ November 7, [removed]Theravance, Inc., and Astellas Pharma Inc. announced t

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2008-09-18 21:56:16
3Theravance and Astellas Announce FDA Approval of VIBATIV™ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections SOUTH SAN FRANCISCO, CA and DEERFIELD, IL – September 11, 2009 – Theravance

Theravance and Astellas Announce FDA Approval of VIBATIV™ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections SOUTH SAN FRANCISCO, CA and DEERFIELD, IL – September 11, 2009 – Theravance

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2009-09-13 21:20:55
4Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections SOUTH SAN FRANCISCO, CA and DEERFIELD, IL/OCTOBER 22, 2007 – Theravance, Inc. (NASDAQ: THRX)

Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections SOUTH SAN FRANCISCO, CA and DEERFIELD, IL/OCTOBER 22, 2007 – Theravance, Inc. (NASDAQ: THRX)

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2008-09-18 20:34:44
5Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/October 28, 2009

Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/October 28, 2009

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2009-10-28 20:07:57
6Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/July 18, [removed]Theravance, Inc. (NASDAQ: THRX), and Astellas

Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/July 18, [removed]Theravance, Inc. (NASDAQ: THRX), and Astellas

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2008-09-19 00:50:37
7Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/May 1, 2007 – Astellas Pharma Inc. (Aste

Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/May 1, 2007 – Astellas Pharma Inc. (Aste

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2008-09-18 21:25:49
8Astellas Receives European Marketing Authorisation for VIBATIV® for Nosocomial Pneumonia Caused by MRSA1 Staines, United Kingdom, September 15, 2011 – Astellas Pharma Europe Ltd., a subsidiary of Tokyo based Astellas

Astellas Receives European Marketing Authorisation for VIBATIV® for Nosocomial Pneumonia Caused by MRSA1 Staines, United Kingdom, September 15, 2011 – Astellas Pharma Europe Ltd., a subsidiary of Tokyo based Astellas

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2011-09-14 22:51:12
9  Changes to EUCAST telavancin breakpoints for S. aureus following changes to MIC methodology In Europe, telavancin is indicated for the treatment of adults with hospital-acquired pneumonia, including ventilator associ

  Changes to EUCAST telavancin breakpoints for S. aureus following changes to MIC methodology In Europe, telavancin is indicated for the treatment of adults with hospital-acquired pneumonia, including ventilator associ

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2014-07-07 07:41:07
10The committee will discuss new drug application (NDA[removed], telavancin sterile powder for injection, application submitted by Theravance, Incorporated, and the requested indication of nosocomial pneumonia, including ven

The committee will discuss new drug application (NDA[removed], telavancin sterile powder for injection, application submitted by Theravance, Incorporated, and the requested indication of nosocomial pneumonia, including ven

Add to Reading List

Source URL: www.fda.gov

Language: English